Ads
related to: pacing induced cardiomyopathy management- Heart Failure Stages
Access Our Heart Failure Guide.
Learn About Heart Failure Stages.
- Heart Failure Treatment
Download Our Free Treatment Guide.
Discover Options for Heart Failure.
- Heart Failure Symptoms
Access a Free Treatment Guide.
Understand Heart Failure Symptoms.
- Living With Heart Failure
Access a Heart Failure Guide.
Learn About Treatment Options.
- Heart Failure Stages
Search results
Results From The WOW.Com Content Network
This includes patients with cardiomyopathy (hypertensive, hypertrophic, restrictive) and elderly individuals. [5] [7] [10] [12] Other factors correlated with development of pacemaker syndrome include decreased stroke volume, decreased cardiac output, and decreased left atrial total emptying fraction associated with ventricular pacing. [5] [10]
Tachycardia-induced cardiomyopathy (TIC) is a disease where prolonged tachycardia (a fast heart rate) or arrhythmia (an irregular heart rhythm) causes an impairment of the myocardium (heart muscle), which can result in heart failure.
Management of ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) focuses on symptoms management, as no treatments that address the root cause of the illness are available. [ 1 ] : 29 Pacing, or regulating one's activities to avoid triggering worse symptoms, is the most common management strategy for post-exertional malaise .
For patients with more than 1,000 PVCs per day, the risk of developing left ventricular systolic dysfunction after 5 years follow-up is low. Frequent PVCs may increase the risk of developing cardiomyopathy, which can greatly impair heart function. A PVC burden greater than 10% is the minimal threshold for development of PVC-induced cardiomyopathy.
Myocardial stunning or transient post-ischemic myocardial dysfunction is a state of mechanical cardiac dysfunction that can occur in a portion of myocardium without necrosis after a brief interruption in perfusion, despite the timely restoration of normal coronary blood flow.
Preventative measures for anthracycline induced cardiomyopathy include dexrazoxane, which is the only preventative drug approved by the FDA for prevention of anthracycline cardiomyopathy. [14] Overall, there are no specific treatments targeted towards the cardiotoxicity of anticancer drugs.
Ad
related to: pacing induced cardiomyopathy management